Merck (MRK) Capital Expenditures (2009 - 2026)

Merck (MRK) has 18 years of Capital Expenditures data on file, last reported at $991.0 million in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $991.0 million, down 25.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.8 billion (down 1.67% YoY), and the FY2025 annual result was $4.1 billion, up 21.95% from the prior year.
• Capital Expenditures declined to $991.0 million in Q1 2026 per MRK's latest filing, from $1.0 billion in the prior quarter.
• Over five years, Capital Expenditures peaked at $1.3 billion in Q1 2025 and troughed at $764.0 million in Q2 2025.
• A 5-year average of $983.9 million and a median of $987.0 million in 2025 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2025 and 2026: Capital Expenditures jumped 54.24% in 2025, then slipped 25.38% in 2026.
• A 5-year view of Capital Expenditures shows it stood at $1.1 billion in 2022, then decreased by 13.93% to $989.0 million in 2023, then retreated by 5.26% to $937.0 million in 2024, then gained by 10.25% to $1.0 billion in 2025, then declined by 4.07% to $991.0 million in 2026.
• Business Quant data shows MRK's Capital Expenditures at $991.0 million in Q1 2026, $1.0 billion in Q4 2025, and $987.0 million in Q3 2025.